Adalvo announces commencement of DCP procedure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet

09 March 2022

Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst the first companies to launch this product on the market in EU.

Our niche peptide product has been developed based on the reference brand Minirin Melt from Ferring which is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis and nocturia. The brand sold $125mio globally in 2021, according to IQVIA.

Adalvo is one of the very few companies working on this complex niche peptide product which underpins Adalvo's robust R&D strengths and capabilities, and demonstrates our ability to continuously offer highly differentiated, value-added niche products to our partners.